公开(公告)号：US20160297837A1

公开(公告)日：2016-10-13

申请号：US15100825

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Rikki Peter Alexander ,  Jonathan Mark Bentley ,  Gareth Neil Brace ,  Daniel Christopher Brookings ,  Praful Tulshi Chovatia ,  Hervé Jean Claude Deboves ,  Craig Johnstone ,  Elizabeth Pearl Jones ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  James Madden ,  Craig Miller ,  John Robert Porter ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Darshan Gunvant Vaidya ,  Ian Andrew Yule

IPC: C07D519/00 ,  A61K31/4709 ,  A61K31/4355 ,  A61K31/538 ,  A61K31/5383 ,  C07D471/04

CPC classification number: C07D519/00 ,  A61K31/4355 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D471/04

Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 一系列取代的苯并咪唑，咪唑并[1,2-a]吡啶和吡唑并[1,5-a]吡啶衍生物及其类似物是人类TNFα活性的有效调节剂，因此在治疗和/或预防中有益 各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。

公开(公告)号：US09868749B2

公开(公告)日：2018-01-16

申请号：US15100825

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Rikki Peter Alexander ,  Jonathan Mark Bentley ,  Gareth Neil Brace ,  Daniel Christopher Brookings ,  Prafulkumar Tulshibhai Chovatia ,  Hervé Jean Claude Deboves ,  Craig Johnstone ,  Elizabeth Pearl Jones ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  James Madden ,  Craig Miller ,  John Robert Porter ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Darshan Gunvant Vaidya ,  Ian Andrew Yule

IPC: C07D519/00 ,  C07D471/04 ,  A61K31/4355 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

CPC classification number: C07D519/00 ,  A61K31/4355 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D471/04

Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US10287299B2

公开(公告)日：2019-05-14

申请号：US15580059

申请日：2016-06-07

Applicant: UCB Biopharma SPRL

Inventor： Gareth Neil Brace ,  Prafulkumar Tulshibhai Chovatia ,  Gregory Foulkes ,  James Andrew Johnson ,  Severine Danielle Jones ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  Pui Leng Loke ,  Martin Alexander Lowe ,  Ajay Mandal ,  Timothy John Norman ,  Christopher Francis Palmer ,  Yolanda Pérez-Fuertes ,  John Robert Porter ,  Donald Smyth ,  Giancarlo Trani ,  Muhammed Uddin ,  Zhaoning Zhu

IPC: A61K31/5365 ,  C07D265/36 ,  C07D498/04 ,  C07D401/06 ,  C07D413/06 ,  A61P27/02 ,  A61P3/00 ,  A61P9/00 ,  A61P23/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61K31/423 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/55 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D519/00

Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US10087179B2

公开(公告)日：2018-10-02

申请号：US15101767

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Rikki Peter Alexander ,  Gareth Neil Brace ,  Julien Alistair Brown ,  Mark Daniel Calmiano ,  Prafulkumar Tulshibhai Chovatia ,  Michael Deligny ,  Ellen Olivia Gallimore ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Malcolm MacCoss ,  Joanna Rachel Quincey ,  Yogesh Anil Sabnis ,  Dominique Louis Léon Swinnen ,  Zhaoning Zhu ,  Uwe Heinelt ,  Volkmar Wehner

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/437

Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20180134728A1

公开(公告)日：2018-05-17

申请号：US15580059

申请日：2016-06-07

Applicant: UCB Biopharma SPRL

Inventor： Gareth Neil Brace ,  Prafulkumar Tulshibhai Chovatia ,  Gregory Foulkes ,  James Andrew Johnson ,  Severine Danielle Jones ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  Pui Leng Loke ,  Martin Alexander Lowe ,  Ajay Mandal ,  Timothy John Norman ,  Christopher Francis Palmer ,  Yolanda Pérez-Fuertes ,  John Robert Porter ,  Donald Smyth ,  Giancarlo Trani ,  Muhammed Uddin ,  Zhaoning Zhu

IPC: C07D498/04 ,  A61P29/00 ,  A61P25/00 ,  A61P3/00 ,  A61P27/02 ,  A61P23/00 ,  A61P9/00 ,  A61P35/00 ,  A61K31/5383 ,  C07D413/14 ,  A61K31/538 ,  C07D413/06 ,  C07D471/04 ,  C07D413/12 ,  A61K31/473 ,  A61K31/4375 ,  A61K31/4725 ,  A61K31/444 ,  A61K31/423 ,  A61K31/4545 ,  A61K31/55 ,  C07D519/00

CPC classification number: C07D498/04 ,  A61K31/423 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/55 ,  A61P3/00 ,  A61P9/00 ,  A61P23/00 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  C07D401/06 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D519/00

Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.